1-adamantylguanidine hydrochloride

IEM-2151 (1-adamantylguanidine hydrochloride) is a small molecule guanidine derivative of adamantane that functions as a non-competitive NMDA receptor antagonist. Developed by researchers at the Institute of Experimental Medicine, it is primarily investigated for its antiparkinsonian properties. In preclinical rat models of rotenone-induced parkinsonism, IEM-2151 has demonstrated superior efficacy compared to memantine and levodopa in reducing motor deficits such as oligokinesia and catalepsy. It also exhibits a favorable safety profile, preventing lethality in experimental models where other treatments increased it. Furthermore, IEM-2151 shows a significant synergistic effect when combined with low doses of levodopa, suggesting it may be a viable candidate for treating levodopa-refractory Parkinson's disease.

Other names

1-adamantylguanidine1-guanidinoadamantane hydrochloride